Phase II trial of erythropoietin (ErepoXen) in patients with anaemia associated with chronic kidney disease

Trial Profile

Phase II trial of erythropoietin (ErepoXen) in patients with anaemia associated with chronic kidney disease

Recruiting
Phase of Trial: Phase II

Latest Information Update: 10 Oct 2016

At a glance

  • Drugs Erythropoietin (Primary)
  • Indications Anaemia
  • Focus Adverse reactions; Therapeutic Use
  • Sponsors Xenetic Biosciences
  • Most Recent Events

    • 10 Oct 2016 Topline results from cohort 3 published in a Xenetic Biosciences media release.
    • 08 Oct 2014 New trial record
    • 11 Aug 2014 Tolerability results in the first cohort published in a Xenetic Biosciences media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top